Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

Relapse remains the main cause of treatment failure in acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Emerging evidence has demonstrated that AML patients might benefit from maintenance therapy post-transplantation, especially for high-risk AM...

Descripción completa

Detalles Bibliográficos
Autores principales: Xuan, Li, Liu, Qifa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786934/
https://www.ncbi.nlm.nih.gov/pubmed/33407700
http://dx.doi.org/10.1186/s13045-020-01017-7
_version_ 1783632728455905280
author Xuan, Li
Liu, Qifa
author_facet Xuan, Li
Liu, Qifa
author_sort Xuan, Li
collection PubMed
description Relapse remains the main cause of treatment failure in acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Emerging evidence has demonstrated that AML patients might benefit from maintenance therapy post-transplantation, especially for high-risk AML patients. In this mini-review, we will summarize targeted drugs, such as hypomethylating agents, FLT3 inhibitors and isocitrate dehydrogenase inhibitors, as maintenance therapy post-transplantation in AML patients undergoing allo-HSCT.
format Online
Article
Text
id pubmed-7786934
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77869342021-01-07 Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation Xuan, Li Liu, Qifa J Hematol Oncol Review Relapse remains the main cause of treatment failure in acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Emerging evidence has demonstrated that AML patients might benefit from maintenance therapy post-transplantation, especially for high-risk AML patients. In this mini-review, we will summarize targeted drugs, such as hypomethylating agents, FLT3 inhibitors and isocitrate dehydrogenase inhibitors, as maintenance therapy post-transplantation in AML patients undergoing allo-HSCT. BioMed Central 2021-01-06 /pmc/articles/PMC7786934/ /pubmed/33407700 http://dx.doi.org/10.1186/s13045-020-01017-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Xuan, Li
Liu, Qifa
Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
title Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
title_full Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
title_fullStr Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
title_full_unstemmed Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
title_short Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
title_sort maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786934/
https://www.ncbi.nlm.nih.gov/pubmed/33407700
http://dx.doi.org/10.1186/s13045-020-01017-7
work_keys_str_mv AT xuanli maintenancetherapyinacutemyeloidleukemiaafterallogeneichematopoieticstemcelltransplantation
AT liuqifa maintenancetherapyinacutemyeloidleukemiaafterallogeneichematopoieticstemcelltransplantation

Ejemplares similares